CDSL Penalty, L&T Mega Orders and Q1 Earnings Set Up a High-Impact Trading Day

Markets Set the Stage Indian benchmarks ended lower on Monday, with the Nifty50 slipping 95.80 points to 24,238.50 and the Sensex falling 442.93 points to 77,708.52, as weak private-bank earnings and Middle East tensions weighed on sentiment.

Market breadth stayed positive, with 2,141 advancing stocks against 1,944 decliners. Technically, the 24,300–24,400 zone, aligned with the 200-day EMA, remains the immediate hurdle, while support holds at 24,000–23,800. Against that backdrop, several company-specific developments are likely to drive stock selection on Tuesday.

Key Highlights

• SEBI fined CDSL ₹1 crore over cybersecurity lapses tied to the November 2022 malware attack that disrupted settlement systems for nearly 47 hours.
• L&T’s Metals & Minerals arm won three orders worth ₹10,000–15,000 crore each, spanning iron ore, steel and zinc processing.
• Grasim has deployed nearly ₹74,000 crore in capex over five years; FY26 revenue hit a record ₹1,75,431 crore.
• Emcure’s Poviztra received CDSCO approval for fatty liver disease (MASH), the first GLP-1 drug cleared for the condition in India.
• IndiGo signed an MoU for 1,000+ LEAP-1A engines with CFM International, its largest-ever single engine order.
• Adani Energy Solutions, Adani Total Gas, Bajaj Auto and others report Q1 FY27 results today.
• Nifty50 closed 0.39% lower at 24,238.50 on Monday as private bank earnings disappointed.

  

CDSL Fined ₹1 Crore Over 2022 Cybersecurity Breach

SEBI has imposed a ₹1 crore penalty on Central Depository Services for cybersecurity and operational lapses linked to the November 2022 malware attack.

The regulator’s order found the breach disrupted CDSL’s settlement process for nearly 47 hours and inter-depository transfers for close to 55 hours, with a major spillover impact on the securities market.

SEBI noted the attacker had accessed CDSL’s servers as early as November 2021, a year before detection, and treated the incident as the foreseeable result of accumulated lapses rather than a one-off failure.

CDSL has not issued a detailed public response yet, leaving open how the depository plans to address the findings.

Check Live: CDSL Option Chain (CDSL) — Live OI, IV, Greeks & PCR

L&T Wins Up to ₹15,000-Crore Mega Orders

L&T’s Metals & Minerals vertical has secured multiple mega orders, each valued ₹10,000–15,000 crore under the company’s own classification, from public and private sector clients.

The largest is Package BE-01C for an 18 MTPA iron ore handling plant in Chhattisgarh, awarded by India’s largest public sector iron ore producer as it scales toward 100 MTPA capacity by 2030.

A second Navratna PSU has ordered a West Bengal steel plant expansion from 2.5 to 7.1 MTPA, while a private metals major awarded an EPC contract for a zinc processing plant.

CMD S N Subrahmanyan called the wins a reflection of customer trust in L&T’s execution capability; the stock traded near ₹3,821 on the NSE. Execution timelines and metals-segment margins will be the key variables to track through FY27.

Check Live: LARSEN & TOUBRO Option Chain (NSE) — Live OI, PCR & Greeks

Grasim’s ₹74,000-Crore Capex Cycle Nears Completion

Grasim Industries has invested nearly ₹74,000 crore in capex over the past five years, chairman Kumar Mangalam Birla said, largely funding paints business Birla Opus and B2B platform Birla Pivot.

FY26 consolidated revenue rose to a record ₹1,75,431 crore, with EBITDA up 29% year-on-year.

With the heaviest investment phase largely behind it, management’s focus is shifting toward asset efficiency and free cash flow, a transition that will be tested as the newer businesses move from build-out to profitability.

Check Live: GRASIM INDUSTRIES Options Chart

Emcure’s Poviztra Gets Nod for Fatty Liver Disease

Emcure Pharmaceuticals said its co-marketed semaglutide brand Poviztra has received CDSCO approval to treat non-cirrhotic MASH with moderate to advanced liver fibrosis, making semaglutide the first GLP-1 receptor agonist cleared in India for the condition.

The approval draws on the global Phase III ESSENCE trial, which showed steatohepatitis resolution in 63% of patients and fibrosis improvement in 37%. Emcure, whose FY26 revenue grew 16.6% year-on-year to ₹9,204 crore, cut Poviztra’s starting monthly price by 55% to ₹3,999 in April ahead of expected generic competition.

The new indication will be marketed via subsidiary Zuventus Healthcare. Actual revenue impact will hinge on hepatologist adoption speed and how domestic generics affect pricing.

Also in Focus: IndiGo, IOB, Redington

InterGlobe Aviation (IndiGo) signed an MoU with CFM International for over 1,000 LEAP-1A engines to power 510 Airbus A320neo-family aircraft, the largest single LEAP order in CFM’s history, with plans for a dedicated IndiGo engine MRO facility in India.

Indian Overseas Bank expects to raise $600–650 million in FCNR deposits by September, up from $300 million currently, after posting a 49.3% year-on-year jump in Q1 net profit to ₹1,659 crore.

Redington has entered a five-year distribution partnership with Resulticks to expand real-time customer engagement technology across India, the Middle East and South-East Asia, targeting a combined market opportunity of over $150 million.

Q1 Results Today: Adani Energy, Adani Total Gas, Bajaj Auto in Focus

Adani Energy Solutions, Adani Total Gas, Bajaj Auto, Bandhan Bank, TVS Motor, JSW Infrastructure, M&M Financial Services, Aditya Birla Sun Life AMC, Anthem Biosciences, Indian Hotels, Crisil, Mastek and Trident are among companies reporting June-quarter results today, adding to an earnings season already marked by weak private-bank numbers.

NiftyTrader Desk View

Source: SEBI order, company exchange filings, NSE/BSE data

Track today’s institutional activity on NiftyTrader’s FII-DII Tracker as PSU banks lead sectoral gains while private banks stay under pressure.

Key Things to Watch

• Nifty’s ability to close above the 24,300–24,400 resistance zone
• Any formal CDSL response or appeal to SEBI’s order
• Execution and margin guidance from L&T on its new metals orders
• Early prescription trends for Poviztra’s MASH indication
• Progress on IndiGo’s LEAP MoU toward a firm order
• Q1 numbers from Adani Energy Solutions, Adani Total Gas and remaining private banks

Why It Matters Today

CDSL’s penalty renews scrutiny of cybersecurity standards at market infrastructure institutions as digital transaction volumes keep rising.

L&T’s order haul and IndiGo’s record engine deal both signal sustained capex momentum in infrastructure and aviation.

Emcure’s approval opens a new growth lever in a metabolic-disease category pharma investors have tracked closely since Wegovy’s own MASH clearance last week.

Final Take

None of today’s stories is likely to move the Nifty on its own, but together they reflect a market where earnings and regulatory catalysts, not index direction, are driving stock selection.

The real test comes as more Q1 numbers land through the week: private banks have already disappointed once, and a repeat from names still to report could keep the index pinned below 24,400 even as stock-specific stories like L&T’s, IndiGo’s and Emcure’s draw interest.

Bottom Line

CDSL’s cybersecurity penalty, L&T’s mega orders, Grasim’s capex update, Emcure’s MASH approval and IndiGo’s record engine order give traders concrete triggers on a day when the Nifty stays range-bound between 23,800 and 24,400, with Q1 earnings from Adani Energy Solutions, Adani Total Gas and Bajaj Auto due later today.

This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decisions.